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Impaired response of the denervated kidney to endothelin re-
ceptor blockade in normotensive and spontaneously hyperten-
sive rats.
Background. As yet, there are only limited data available on
the exact role of endothelin (ET) acting through endothelin-
A (ETA) receptors in renal sodium and water regulation and
the potential functional implications of an interaction of the
renal ET system with renal nerves in normotensive and spon-
taneously hypertensive rats.
Methods. Experiments were carried out in 64 male conscious
spontaneously hypertensive rats and in 56 normotensive Wistar-
Kyoto (WKY) rats. Bilateral renal denervation (BRD) was per-
formed in 32 spontaneously hypertensive rats and 28 WKY rats
7 days before the experiments. The ETA receptor antagonist,
BQ-123 (16.4 nmol/kg.min intravenously) or the endothelin-
B (ETB) receptor antagonist, BQ-788 (25 nmol/kg.min intra-
venously) were infused at a rate of 25 lL/min for 50 minutes.
Results. Renal papillary ET-1 concentration in intact sponta-
neously hypertensive rats was 67.8% lower than in intact WKY
rats (154 ± 40 fmol/mg protein vs. 478 ± 62 fmol/mg protein,
P < 0.01). BRD decreased papillary ET-1 by 73.5% in WKY
rats to 127 ± 19 fmol/mg protein (P < 0.001), but had no effect
in spontaneously hypertensive rats (122 ± 37 fmol/mg protein).
BRD, BQ-123, or BQ-788 did not affect glomerular filtration
rate (GFR) or renal blood flow (RBF) in any of the groups. In
intact WKY, BQ-123 decreased urine flow rate (V) from 4.65 ±
0.44 lL/min.100 g body weight to 2.44 ± 0.35 lL/min.100 g
body weight (P < 0.01), urinary excretion of sodium (UNaV)
from 238.2 ± 27.4 to 100.2 ± 17.0 (P < 0.01) and potassium
(UKV) from 532.1 ± 62.6 nmol/min.100 g body weight to 243.0 ±
34.2 nmol/min.100 g body weight (P < 0.001), whereas BQ-
788 decreased only V and UNaV. In renal denervated WKY,
BQ-123 or BQ-788 did not alter V, UNaV, or UKV. In intact
spontaneously hypertensive rats BQ-123 but not BQ-788 de-
creased V from 3.94 ± 0.48 lL/min.100 g body weight to 2.55 ±
0.44 lL/min.100 g body weight (P < 0.05). In renal denervated
spontaneously hypertensive rats neither BQ-123 nor BQ-788
affected V, UNaV, or UKV.
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Conclusion. An interaction between ET and renal nerves is
involved in the control of renal function. Moreover, renal nerves
participate in the regulation of ET-1 production within the kid-
ney. Finally, decreased synthesis of ET-1 in the renal papilla
of spontaneously hypertensive rats may contribute to develop-
ment and/or maintenance of hypertension due to modulation
of renal excretory function.
Numerous studies have provided strong evidence for
a close relationship between hypertension and impaired
renal function. Thus, it was clearly demonstrated that the
kidney of spontaneously (i.e., genetically) hypertensive
rats plays a key role in the maintenance of hypertension
[1].
Kidneys are known to be richly innervated by the sym-
pathetic nervous system and renal nerves produce alter-
ations in renal hemodynamics, tubular reabsorption, and
renin secretion that importantly contribute to renal adap-
tation to physiologic and pathologic stimuli [2]. Thus,
stimulation of efferent renal nerves alters renal hemo-
dynamics, enhances tubular fluid and electrolyte absorp-
tion throughout the nephron with decreased water and
sodium excretion, and increases renin secretion. With re-
spect to their possible role in hypertension it has been
demonstrated that renal nerve activity of young sponta-
neously hypertensive rats is augmented and contributes
to the development of hypertension by enhancing renal
salt retention [3]. Moreover, kidney denervation in spon-
taneously hypertensive rats during the prehypertensive
stage delays and attenuates the development of hyper-
tension [4]. Thus, it is likely that increased renal nerve
activity is involved in the pathogenesis of hypertension.
It is now well established that endothelin (ET) is dis-
tributed in a variety of organs and tissues including the
kidney [5], where it can influence renal hemodynamics
and tubular function [6]. In recent years it has become
apparent that ET-1 plays a major role in salt-dependent
hypertension by modulating renal salt and water excre-
tion [7]. Thus, there is accumulating evidence suggesting
that the ET system plays an important role in the develop-
ment and maintenance of hypertension in animal models
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such as the deoxycorticosterone acetate (DOCA)-salt-
induced hypertensive rat [8] and the Dahl salt-sensitive
rat [7]. In contrast to these models it remains unclear
whether the renal ET system and to what extent it par-
ticipates in the pathogenesis of hypertension in spon-
taneously hypertensive rats. In particular, it is unclear
whether an interaction of the renal ET system with re-
nal nerves is of significance for the regulation of renal
excretory function during the development of sponta-
neous hypertension. Especially the mode of this inter-
action with respect to the intrarenal ET-1 distribution as
well as its relative contribution to the development and/or
maintenance of spontaneous hypertension remain largely
unknown.
In the kidney both endothelin-A (ETA) and
endothelin-B (ETB) receptors mediate the renal effects
of ET-1 [6]. Recent evidence suggests that the effects of
ET-1 on water and sodium excretion are mediated es-
sentially through ETB receptors [9, 10]. So far, only few
studies have investigated the effects of ETA receptor in-
hibition on renal excretory function and these studies
do not provide unequivocal data to conclude that ETA
receptors also contribute to the diuretic or natriuretic ac-
tions of ET-1.
Therefore, the present study was performed first to in-
vestigate the role of the renal ET system and especially
the involvement of ETA receptors in the regulation of
renal excretory function in normotensive and sponta-
neously hypertensive rats. For this purpose, the selective
ETA receptor antagonist BQ-123 was used to determine
the effects of ETA receptor blockade on renal sodium
and water handling and its effects were compared with
those of ETB receptor blockade with BQ-788.
Second, in the present study we determined the influ-
ence of renal nerves on the ET-1 content in renal cortex
and papilla of normotensive and spontaneously hyper-
tensive rats. Third, in order to determine the significance
of an interaction between renal nerves and the renal ET
system in the regulation of renal excretory function and
renal hemodynamics, the selective ETA and ETB receptor
antagonists, BQ-123 and BQ-788, were applied to con-
scious intact as well as to renal denervated normotensive
and spontaneously hypertensive rats.
METHODS
Conscious, male spontaneously hypertensive rats, and
Wistar-Kyoto (WKY) rats, weighing between 280 to 320 g
were used. They were kept in individual cages for a mini-
mum of 1 week before experiments were started. The rats
were given a normal rat chow and tap water. The study
was performed following approval by the state animal
protection board at the Bezirksregierung Cologne, Fed-
eral Republic of Germany, as well as in accordance with
institutional care and use of laboratory animals guide-
lines, Medical University, Sofia, Bulgaria. For surgical
preparation, the rats were anesthetized with pentobarbi-
tal sodium (Narcoren) 40 mg/kg body weight given in-
traperitoneally. In part of the rats, both kidneys were
denervated prior to vascular and bladder catheteriza-
tion. Bilateral renal denervation (BRD) was performed
retroperitoneally after flank incision. After careful dis-
section of renal vessels, all visible nerve fibers were re-
moved. Thereafter, the renal vessels were coated with
10% phenol in absolute alcohol. One week was allowed
for the rats to recover. Sham-operated WKY and spon-
taneously hypertensive rats were subjected only to flank
incisions, but renal nerves were left intact. For urine col-
lection, a modified polyethylene catheter was placed into
the urinary bladder through a suprapubic incision, fixed
by sutures to adjacent muscle, subcutaneous tissue and
skin, and exteriorized at the back of the neck. For drug
and solute infusion and for blood pressure measurement,
catheters were placed into the femoral vein and into the
femoral artery, respectively, and were tunnelled to the
back of the neck and then exteriorized. The femoral vein
catheter was connected to an infusion pump set to deliver
0.9% NaCl solution at a rate of 25 lL/min for the duration
of the surgical preparation. To avoid clotting of catheters
in the freely moving animals, the femoral artery and vein
catheters were flushed with heparin in 0.9% sterile saline.
The experiments were performed 1 day after catheter
implantation in conscious normotensive and hyperten-
sive rats without and with BRD placed in individual
restraining plastic cages. The selective ETA receptor
antagonist BQ-123 and the selective ETB receptor an-
tagonist BQ-788 (Calbiochem) were applied through
the femoral vein cannula. Urine was collected into
preweighed tubes during a first 40-minute clearance pe-
riod before administration of ET receptor blockers or
vehicle. Ten minutes after the start of the infusion of ET
receptor blockers or vehicle, urine was collected again
during a second 40-minute clearance period. At the end of
the experiment, under pentobarbital anesthesia, 40 mg/
kg body weight, blood was drawn by cardiac puncture
and the kidneys were removed and rapidly dissected on
an ice-cold glass plate to obtain cortical and papillary
tissues which were then frozen immediately in liquid ni-
trogen and stored at –70◦C.
Spontaneously hypertensive rats and WKY rats were
divided into six experimental groups undergoing differ-
ent treatments. The first group of intact rats, 11 WKY rats
and 13 spontaneously hypertensive rats, and the second
group of rats with BRD, 11 WKY rats and 13 sponta-
neously hypertensive rats, received vehicle (0.9% sodium
chloride) at a pump rate of 25 lL/min.
Intravenous treatment with the ETA receptor antago-
nist BQ-123, 16.4 nmol/kg.min at an infusion rate of 25 lL/
min for 50 minutes, was performed in the third group of in-
tact rats, 11 WKY rats and 13 spontaneously hypertensive
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rats, and in the fourth group of rats with BRD, 11 WKY
rats and 13 spontaneously hypertensive rats. Intravenous
treatment with the ETB receptor antagonist BQ-788,
25 nmol/kg.min at an infusion rate of 25 lL/min for
50 minutes, was performed in the fifth group of in-
tact rats, six WKY rats and six spontaneously hyper-
tensive rats, and in the sixth group of rats with BRD,
six WKY rats and six spontaneously hypertensive rats.
Doses of BQ-123 [11] and BQ-788 [12] used in the present
study, were previously shown not to affect arterial blood
pressure.
For time control experiments urine was collected over
a time period of 90 minutes in both intact WKY rats
(N = 10) and spontaneously hypertensive rats (N = 10)
as well as renal-denervated WKY rats (N = 9) and spon-
taneously hypertensive rats (N = 9).
Arterial blood pressure was monitored in all groups
using a Gould/Statham P23ID pressure transducer con-
nected to a catheter in the femoral artery. After analogue-
to-digital conversion by a data acquisition system Biopac
MP100WS, systolic blood pressure, diastolic blood pres-
sure, and mean arterial pressure (MAP) were estimated.
These variables were stored online on a computer disc
and continued analysis by Biopac AcqKnowledge soft-
ware was made. Urine volume was assessed gravimetri-
cally to estimate urine flow rate (V).
Hematocrit was obtained from all blood samples.
Plasma and urine concentrations of sodium and potas-
sium were determined by flame photometry (Corning
410C). Osmolality was determined by using a vapor
pressure osmometer (Vescor 5500A). On the basis of
these data urinary excretion rates of sodium (UNaV)
and potassium (UKV) as well as urinary osmolyte ex-
cretion (UosmV) were calculated. The effectiveness of
renal denervation was assessed by determination of re-
nal tissue norepinephrine content [2]. For this purpose,
catecholamines were concentrated and purified by se-
lective adsorption onto aluminum oxide, and after that
fluorescent norepinephrine derivatives were formed and
determined spectrofluorometrically [13, 14]. Renal den-
ervation resulted in reduction of norepinephrine content
from an average of 5.48 ± 0.31 in each 10 WKY rats and
spontaneously hypertensive rats to 0.24 ± 0.12 nmol/g re-
nal tissue in each nine renal-denervated WKY rats and
spontaneously hypertensive rats (P < 0.001).
Plasma and urine concentrations of inulin were deter-
mined by the anthrone method [15]. Glomerular filtration
rate (GFR) was estimated by the clearance of inulin. Uri-
nary and plasma concentrations of para-aminohippurate
(PAH) were determined by the modified method of Smith
et al [16]. Effective renal plasma flow (ERPF) was esti-
mated from the clearance of PAH and renal blood flow
(RBF) was calculated as ERPF/1-hematocrit.
In six rats of each group, plasma and urine as well as tis-
sue concentrations of ET-1 were determined by enzyme-
linked immunosorbent assay (ELISA) (Endothelin-
1 ELISASystem) (Amersham Buchler, Braunschweig,
Germany) as previously described [17]. For ET-1 deter-
mination in renal cortex and papilla, tissues were ho-
mogenized on ice at 4◦C in distilled water containing 100
kallikrein-inhibitory units/mL of aprotinin using a 2 mL
glass homogenizer (Kontes, Vineland). The homogenates
were then centrifuged at 600g for 10 minutes. The su-
pernatants were extracted using Sep-Pak C18 cartridges
with 70% (vol/vol) methanol and ET-1 concentration was
determined by ELISA. For protein determination, the
pellets were resuspended in 5 mL of 1% (wt/vol) sodium
dodecyl sulfate (SDS) for bicinchoninic acid protein assay
(Pierce, Rockford, IL, USA) according to the instructions
of the manufacturer. All chemicals used were purchased
from Sigma Co. (Diesenhofen, Germany).
Statistical analysis was performed using Student t test,
Wilcoxon test for unpaired data, or one-way analysis of
variance (ANOVA) (Tadpole computer program, Else-
vier Publishers, Amsterdam, The Netherlands) when ap-
propriate. Results are presented as mean ± SEM. Differ-
ences at a level of P < 0.05 were considered statistically
significant.
RESULTS
Throughout the time control experiments, sponta-
neously hypertensive rats and WKY rats with innervated
or denervated kidneys showed stable arterial blood pres-
sure and renal excretory function. Values from time con-
trol experiments were not different from control periods
in either the intact or the BRD experimental groups of
rats.
Systolic and diastolic blood pressure and MAP were
significantly higher in spontaneously hypertensive rats
than in WKY rats (P < 0.001). BRD did not significantly
change blood pressure, GFR or RBF in WKY rats or
spontaneously hypertensive rats (Table 1). ETA receptor
blockade with intravenous BQ-123, 16.4 nmol/kg.min, did
not change systolic or diastolic blood pressure or MAP
in intact or renal denervated WKY rats. BQ-123 admin-
istration in intact and renal denervated spontaneously
hypertensive rats decreased systolic blood pressure only
slightly (P < 0.05), while MAP or diastolic blood pressure
did not change. BQ-123 infusion did not result in changes
in GFR or RBF in intact and renal denervated WKY rats
or spontaneously hypertensive rats (Table 1). Hematocrit
did not change in any of the groups investigated.
Renal denervation in WKY rats was followed by an
increase in urine flow rate from 4.65 ± 0.44 lL/min.100 g
body weight to 6.34 ± 0.59 lL/min.100 g body weight (P <
0.05) and a decrease in urine osmolality (P < 0.05) but had
no effect on renal excretory function in spontaneously
hypertensive rats (Table 1) (Fig. 1).
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Table 1. Blood pressure, RBF (lL/min.100 g body weight), GFR
(lL/min.100 g body weight), urine osmolality, and osmolyte excretion
in conscious intact and renal denervated Wistar-Kyoto WKY rats as
well as intact and renal denervated spontaneously hypertensive rats
(SHR) during intravenous BQ-123 infusion (16.4 nmol/kg/min)
WKY + WKYD +
WKY BQ-123 WKYD BQ-123
Number 11 11 11 11
Systolic blood 143 ± 3 137 ± 3 137 ± 3 136 ± 2
pressure
Diastolic blood 82 ± 3 78 ± 2 83 ± 3 81 ± 2
pressure
MAP 103 ± 2 98 ± 2 104 ± 3 101 ± 2
RBF 3989 ± 372 3973 ± 414 4520 ± 475 4814 ± 458
GFR 805 ± 27 928 ± 89 861 ± 32 871 ± 105
Uosm 941 ± 49 1124 ± 55a 805 ± 42a 949 ± 95
UosmV 4218 ± 301 2250 ± 248a 4792 ± 358 3844 ± 306b
SHR + SHRD +
SHR BQ-123 SHRD BQ-123
Number 13 13 13 13
Systolic blood 183 ± 3a 176 ± 2c 185 ± 2 177 ± 2d
pressure
Diastolic blood 110 ± 2a 109 ± 1 109 ± 2 109 ± 2
pressure
MAP 139 ± 2a 134 ± 2 137 ± 3 134 ± 2
RBF 4256 ± 295 4050 ± 409 4077 ± 383 4024 ± 316
GFR 815 ± 139 832 ± 80 957 ± 92 953 ± 55
Uosm 986 ± 68 954 ± 96 955 ± 65 995 ± 51
UosmV 3432 ± 246 2876 ± 256 4744 ± 316 5383 ± 364
Abbreviations are: WKYD, renal denervated WKY rats; SHRD, renal
denervated SHR; MAP, mean arterial pressure, RBF, renal blood flow; GFR,
glomerular filtration rate; Uosm, urine osmolality, mOsm/kg H2O; UosmV,
osmolyte excretion, nOsm/min.100 g body weight.
Statistically significant difference (P < 0.05) as compared to WKY (a); to
WKY + BQ-123 (b); to SHR (c); and to SHRD (d).
In intact WKY rats BQ-123 decreased urine flow rate
to 2.44 ± 0.35 lL/min.100 g body weight (P < 0.01) and
increased urine osmolality (P < 0.05). Sodium and potas-
sium excretion also decreased from 238 ± 27 to 100 ± 17
(P < 0.01) and from 532 ± 63 nmol/min.100 g body weight
to 243 ± 34 nmol/min.100 g body weight (P < 0.05), re-
spectively, resulting in a decrease of urinary osmolyte ex-
cretion (P < 0.05). In renal denervated WKY rats BQ-123
did not significantly alter neither urine flow rate nor uri-
nary sodium, potassium, or osmolyte excretion. In intact
spontaneously hypertensive rats BQ-123 also led to a de-
crease in urine flow rate from 3.94 ± 0.48 lL/min.100 g
body weight to 2.55 ± 0.44 lL/min.100 g body weight (P <
0.05) but was not accompanied by significant changes in
urinary sodium, potassium, or osmolyte excretion. In re-
nal denervated spontaneously hypertensive rats BQ-123
did not change any of the parameters investigated
(Fig. 1) (Table 1).
Similar to the effect of BQ-123, administration of BQ-
788 decreased urine flow rate and sodium excretion in
intact WKY rats (P < 0.001) (Fig. 1). Urine osmolality
increased from 940 ± 49 mOsm/kg H2O to 1469 ± 249
mOsm/kg H2O (P < 0.05). In renal denervated WKY
rats and in intact and in renal denervated spontaneously
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Fig. 1. Urine flow rate (A) and sodium (B) and potassium (C) excretion
in intact Wistar-Kyoto rats (WKY), spontaneously hypertensive rats
(SHR) and in denervated WKY rats (WKYD) and denervated SHR
(SHRD). Symbols are: () control; () intravenous infusion of 16.4
nmol/kg/min BQ-123; () intravenous infusion of 25 nmol/kg/min BQ-
788. ∗P < 0.05; ∗∗P < 0.01, BQ-123 vs. control; ++P < 0.001, BQ-788
vs. control; #P < 0.05, WKYD vs. WKY.
hypertensive rats BQ-788 was not accompanied by signif-
icant changes in urine flow rate, urinary sodium, potas-
sium, or osmolyte excretion (Fig. 1).
Plasma ET-1 concentrations in intact WKY rats and
spontaneously hypertensive rats were 1.05 ± 0.10 fmol/
mL and 0.90 ± 0.11 fmol/mL and were not altered af-
ter renal denervation (1.01 ± 0.10 fmol/mL and 1.02
± 0.11 fmol/mL, respectively). After BQ-123 admin-
istration plasma ET-1 level in intact WKY rats was
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Fig. 2. Tissue endothelin-1 (ET-1) content in renal cortex (A) and
papilla (B) in intact Wistar-Kyoto rats (WKY), spontaneously hyperten-
sive rats (SHR), and in denervated WKY rats (WKYD) and denervated
SHR (SHRD) (each N = 6). #P < 0.001 WKYD vs. WKY rats; ∗∗P <
0.01 SHR vs. WKY rats; ++P < 0.01 SHRD vs. WKYD.
2.06 ± 0.03 fmol/mL, in renal denervated WKY rats
2.16 ± 0.24 fmol/mL, in intact spontaneously hyperten-
sive rats 2.40 ± 0.35 fmol/mL. and in renal denervated
spontaneously hypertensive rats 1.90 ± 0.38 fmol/mL, re-
spectively (P < 0.05).
Renal cortical ET-1 concentration was low and did
not differ between intact spontaneously hypertensive rats
and WKY rats (0.60 ± 0.14 fmol/mg protein and 0.79 ±
0.08 fmol/mg protein). In renal denervated spontaneously
hypertensive rats it was lower than in renal denervated
WKY rats (0.47 ± 0.11 fmol/mg protein vs. 1.26 ±
0.25 fmol/mg protein; P < 0.01) (Fig. 2).
Renal papillary ET-1 concentration in intact sponta-
neously hypertensive rats was 67.8% lower than in intact
normotensive WKY rats (154 ± 40 fmol/mg protein vs.
478 ± 62 fmol/mg protein, P < 0.01). BRD decreased re-
nal papillary ET-1 concentration by 73.5% in WKY rats
to 127 ± 19 fmol/mg protein (P < 0.001), but had no ef-
fect in spontaneously hypertensive rats (122 ± 37 fmol/mg
protein) (Fig. 2).
Urinary ET-1 excretion in intact WKY rats and spon-
taneously hypertensive rats was 379 ± 35 fmol/24 hours
and 34 ± 12 fmol/24 hours, respectively (P < 0.001). Renal
denervation decreased urinary ET-1 excretion in WKY
rats to 84 ± 13 fmol/24 hours (P < 0.001) but had no
effect in spontaneously hypertensive rats (41 ± 11 fmol/
24 hours).
DISCUSSION
In the present study we found plasma ET-1 levels,
which were similar to those which have been reported
previously in normotensive and spontaneously hyperten-
sive rats [6]. However, since ET-1 is known to act in a
paracrine/autocrine fashion, its plasma concentration is
not indicative of its local action and/or production. There-
fore, determination of tissue ET-1 content in the kidney
should provide a better estimate of local changes in pep-
tide production.
Several studies have provided evidence that implicates
locally produced ET-1 in the renal medulla and papilla in
the development of hypertension [17, 18]. In the present
study we found high ET-1 concentrations in the renal
papilla as compared to renal cortical tissue in both nor-
motensive (WKY) and hypertensive rats. More impor-
tant, however, is the finding that the ET-1 content in the
renal papilla of our spontaneously hypertensive rats was
significantly lower than that of their WKY counterparts.
These data confirm our previous observation of signifi-
cantly lower levels of ET-1 peptide and of preproET-1
mRNA expression in the renal papilla of genetically hy-
pertensive rats [Prague hypertensive (Wistar) rats] than
in renal papillary tissue of their normotensive controls
(Prague normotensive rats) [17]. As in this previous study
the present study again failed to demonstrate a difference
in ET-1 content in renal cortical tissue between sponta-
neously hypertensive rats and WKY rats.
Similar alterations in tissue medullary ET-1 content
were reported by Sasser, Pollock, and Pollock [19] in the
chronic angiotensin II infusion model of hypertension.
High salt diet, or angiotensin II infusion, reduced inner
medullary immunoreactive ET content compared with
control values but increased the renal cortical and outer
medullary ET content and urinary ET excretion. Thus,
chronic elevation in angiotensin levels and sodium in-
take produce a differential effect on immunoreactive ET
levels within the kidney [19]. Therefore, renal tissue ET
levels can be regulated in a very site-specific manner.
In agreement with observations by others [20] we found
that selective ETA receptor blockade with BQ-123 did
not affect blood pressure in normotensive WKY rats but
moderately decreased systolic blood pressure in spon-
taneously hypertensive rats, indicating that the ET sys-
tem does not contribute significantly to the maintenance
of blood pressure in normotensive state but is involved
to some degree in the regulation of high blood pressure
in spontaneous hypertension. The relatively small, de-
crease in systolic blood pressure in the absence of changes
in MAP or diastolic blood pressure is unlikely to affect
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autoregulation of GFR. Accordingly, our data show no
changes in GFR or in RBF both in intact and in renal
denervated WKY and spontaneously hypertensive rats
before and during ETA receptor blockade.
Since the renal medulla in rats [21] and in humans [22]
is rich in ETB receptors and contains ETA and ETB re-
ceptors with an approximate ratio of 30:70, additional
experiments were designed to determine the role of ETB
receptors in the response to denervation in spontaneously
hypertensive rats and WKY rats. For this purpose BQ-788
was used to investigate the effects of ETB receptor block-
ade on renal excretory function and its effects were com-
pared with those of ETA receptor blockade with BQ-123
in intact as well as renal denervated normotensive and
hypertensive rats.
In the rat kidney a role of the ETA receptor in the
regulation of tubular reabsorption of sodium has been
suggested [23]. In the present study BQ-123 infusion de-
creased urine flow rate in both WKY and spontaneously
hypertensive rats, whereas BQ-788 infusion decreased
urine flow rate only in normotensive rats. It appears,
therefore, that ET acts also via ETA receptors to affect
tubular water transport in normotensive and in spon-
taneously hypertensive states. Moreover, our present
results indicate that ETA receptors, in addition to ETB re-
ceptors as shown recently [9, 10], also mediate the actions
of the endogenous ligand ET-1 to inhibit tubular sodium
and potassium reabsorption in normotensive rats. In con-
trast to these results and to our surprise, spontaneously
hypertensive rats revealed an impaired response of tubu-
lar sodium and potassium excretion to ETA as well as
ETB receptor blockade. Referring to the ET-1 content in
renal tissue that we observed we may conclude that the
reduced content of ET-1 in the renal papilla of sponta-
neously hypertensive rats may contribute to the impaired
natriuretic action of this peptide system in spontaneous
hypertension. Thus, since ET-1 has diuretic and natri-
uretic properties when produced locally, the decreased
renal production of ET-1 might be of relevance to the
pathophysiology of hypertension.
With respect to the mechanisms of these diuretic and
natriuretic actions of ET-1 it has been shown recently
that administration of big ET-1 induced diuretic and na-
triuretic responses mediated mainly through stimulation
of nitric oxide production via an ETB receptor-coupled
mechanism [10]. It was demonstrated that ETB receptor
deficiency resulted in large increases in blood pressure
in female and, more pronounced, in male rats, especially
during high salt intake and that increased nitric oxide
synthase (NOS) in inner medullary collecting duct tissue
protects against rises in blood pressure in female rats [24].
In addition, it was found that low-dose ET-1 inhibits renal
epithelial sodium channels through ETB receptor activa-
tion, whereas high-dose ET-1 increased renal epithelial
sodium channel transport through activation of ETA re-
ceptors [25]. Thus, from our present results we conclude
that ET acting through renal tubular ETA receptors also
modulates renal sodium and potassium handling.
It is well recognized that renal nerves contribute sub-
stantially to the control of kidney function. Thus, renal
nerve activity may affect renal hemodynamics, renin re-
lease, and sodium and water excretion [2]. The inner-
vation of proximal and distal convoluted tubules, of the
thick ascending limb of Henle’s loop, as well as of cortical
collecting tubules, is well established [26]. Moreover, the
additional release of norepinephrine into the renal inter-
stitium could be an effective route for the delivery of this
neurotransmitter to its receptors located on the basolat-
eral membrane of renal tubular epithelial cells through-
out the entire length of the renal nephron [2]. Both
a- [27] and b-adrenoceptors [28] are expressed in rat in-
ner medullary collecting duct cells.
Acute as well as chronic renal denervation have been
shown in micropuncture studies to decrease proximal
tubule fluid reabsorption. This effect occurs indepen-
dently of changes in GFR or RBF indicating that renal
nerves directly modulate tubular transport processes [29,
30]. Accordingly, in the present study BRD did not affect
blood pressure, GFR, or RBF in either normotensive or
spontaneously hypertensive rats.
As expected, BRD resulted in a rise in urine flow rate
with a reduction in urine osmolality, which was signifi-
cant in normotensive WKY rats. It was suggested [31]
that in the denervated kidney of conscious dogs a mod-
erate impairment of urine concentration may result from
decreased medullary tonicity since the medullary content
of total solutes per kilogram wet tissue weight was found
to be significantly lower in the denervated kidney than in
the intact kidney. This mechanism may also underly the
greater urine flow rate and lower urine osmolality in our
renal denervated WKY rats.
With respect to an interaction between the renal ET
system and renal nerves our findings show for the first
time that BRD decreases papillary ET concentration in
WKY but not in spontaneously hypertensive rats, whose
tissue ET concentration is already low as we reported
earlier [17] and as was confirmed in the present study. In
support of these changes in papillary ET-1 content, we
found parallel changes in urinary ET-1 excretion, which
thus probably reflects tissue ET-1 synthesis.
With respect to our finding of a reduced papillary ET-1
content in denervated kidneys of WKY rats it has been
demonstrated that ET production in the renal medulla
is modulated by ambient osmolality. Indeed, there is evi-
dence to suggest that increasing the osmolality of the in-
cubation medium with NaCl, but not urea, causes a reduc-
tion in ET-1 release in cultured inner medullary collect-
ing duct cells, but had no effect on ET-1 production by rat
endothelial or mesangial cells [32]. On the other hand, in-
creased extracellular tonicity induced by betaine or urea
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was shown in vitro to stimulate ET synthesis in collecting
duct cells [33] as well as peptide production and mRNA
expression of ET-1 in the inner medullary collecting duct
[34]. From the results of the present in vivo study, it seems
reasonable to speculate that decreased papillary ET-1
concentration in renal denervated WKY rats may have
resulted from reduced medullary and papillary tonicity
that occur after renal denervation. This effect may not be-
come apparent in spontaneously hypertensive rats with
their a priori low ET-1 content in the renal papilla and
may also be obscured by well-known rightward shift of
the pressure-diuresis and pressure-natriuresis curves in
hypertension [35]. Although the precise molecular mech-
anisms responsible for the observed changes in renal
papillary ET-1 concentration cannot be derived from the
results of the current study, our data provide strong evi-
dence for a potential role of an interaction of renal nerves
with the renal ET system in modulating renal function in
normotensive and hypertensive states.
The results from our current study are also consistent
with a role for renal nerves in modulating renal excretory
function with respect to ETA and ETB receptor blockade.
In contrast to the antidiuretic and antinatriuretic effects
of BQ-123 in intact WKY rats, neither BQ-123 nor BQ-
788 administration resulted in changes of renal excretory
function in renal denervated WKY rats or in intact or
renal denervated spontaneously hypertensive rats whose
papillary ET content is low as compared to the intact
WKY rats.
In the kidney ETA receptor mRNA and/or binding sites
have been found not only in renal vessels as would be
expected but also in inner medullary interstitial and col-
lecting duct cells [6] as well as in the descending thin
limb of Henle’s loop of long-looped nephrons [36]. De-
scending thin limbs of long-looped nephrons are located
in close proximity to the thick ascending limbs and thus,
paracrine inhibition of sodium reabsorption could be the
route by which ET-1 exerts its diuretic and natriuretic ef-
fects via ETA receptors [36]. Moreover, there is strong
evidence that ET-1 functions as an autocrine regulator
of sodium and water reabsorption in the collecting duct
and thereby plays an important role in body fluid and
volume regulation [24]. Thus, it is well known that ET is
an inhibitory modulator of the hydro-osmotic action of
arginine-vasopressin (AVP) in renal collecting ducts by
suppressing AVP-induced cyclic adenosine monophos-
phate (cAMP) accumulation in the inner medullary col-
lecting duct [37, 38]. a2-adrenoceptors, also capable of
inhibiting the action of AVP, have been found in the pap-
illary collecting duct [39] and it was demonstrated that
a-adrenergic agonists directly inhibit AVP-mediated wa-
ter permeability in the collecting tubule [40]. Futhermore,
activation of a2-adrenoceptors can suppress cAMP for-
mation stimulated by vasopressin [27]. Thus, not only
ET but also adrenergic stimulation are important de-
terminants for the regulation of renal water excretion.
Moreover, it was shown that the ET system contributes
substantially to the ability of the kidney to control sodium
excretion [24] possibly by inhibition of Na+/K+-ATPase
activity in the inner medullary collecting duct and thick
ascending limb of Henle’s loop [6]. Since both renal
nerves and ET affect cAMP synthesis, this intracellular
mediator may serve as the mutual target for the action of
the renal ET system and of renal nerves to modulate re-
nal fluid and sodium excretion. Thus, a direct interaction
between the renal ET system and renal nerves appears
to be involved in the control of renal excretory function.
Taken together, the data from our present study pro-
vide for the first time substantial evidence that renal
nerves selectively regulate the activity of the ET system
in the rat kidney and that renal denervation results in a
blunted functional response to ETA and ETB receptor
blockade in WKY and spontaneously hypertensive rats.
Moreover, our data show that spontaneously hyperten-
sive rats reveal a blunted response of tubular handling of
sodium and potassium to ETA and ETB receptor block-
ade suggesting an association of hypertension with an
altered intrarenal ET system. Finally, decreased synthe-
sis of ET-1 in the renal papilla of spontaneously hyper-
tensive rats may contribute to enhanced salt and water
reabsorption in the inner medullary collecting duct and
may thereby promote the development and maintenance
of hypertension in spontaneously hypertensive rats.
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